Get startedLog in
    Picture of Immix Biopharma logo

    IMMX — Immix Biopharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Immix Biopharma In-Licenses NXC-201, BCMA-Targeted Next-Generation CAR-T Therapy

    Picture of Immix Biopharma logoImmix Biopharma
    14/12/2022 13:21
    Dec 14 (Reuters) - Immix Biopharma Inc  IMMX.O :
    * IMMIX BIOPHARMA IN-LICENSES NXC-201, BCMA-TARGETED
NEXT-GENERATION CAR-T THERAPY DEMONSTRATING HIGH COMPLETE
RESPONSE RATE IN HEAVILY PRE-TREATED MULTIPLE MYELOMA (71%
COMPLETE RESPONSES) AND AL AMYLOIDOSIS (100% COMPLETE RESPONSES)
    * IMMIX BIOPHARMA INC - FORMS WHOLLY- OWNED SUBSIDIARY
NEXCELLA,
INC TO DEVELOP NXC-201 AND OTHER CAR-T CELL THERAPIES FOR
ONCOLOGY AND OTHER DISEASES
    * IMMIX BIOPHARMA INC - FORMATION OF NEXCELLA, INC IS
EXPECTED TO
HAVE A MINIMAL IMPACT ON CO'S FINANCIAL POSITION
    * IMMIX BIOPHARMA INC - NEXCELLA, INC IS EXPECTED TO BE AN
INDEPENDENTLY FINANCED COMPANY

Source text for Eikon:  ID:nGNX6KHwfw 
Further company coverage:  IMMX.O 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Immix Biopharma

    See all news